<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="561">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>23/09/2005</approvaldate>
  <actrnumber>ACTRN12605000477628</actrnumber>
  <trial_identification>
    <studytitle>ANZ 0201 (TIBER)</studytitle>
    <scientifictitle>ANZ 0201 (TIBER)  An open label, non-comparative, two-arm, phase II trial of ZD1839 (Iressa TM) in patients with hormone insensitive (ER and PgR negative) or hormone resistant (ER and/or PgR positive) metastatic or inoperable locally advanced breast cancer.</scientifictitle>
    <utrn />
    <trialacronym>ANZ 0201 (TIBER)</trialacronym>
    <secondaryid>1839IL/0067</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>ANZ 0201 (TIBER) is a multicentre, open label, non-comparative, two arm phase II trial of ZD 1839 (Iressa TM) 500mg (two 250mg tablets) orally once daily, in two separate patient groups.  Treatment will be administered continuously until clinical or radiological evidence of disease progression, unacceptable toxicity or withdrawal of consent.</interventions>
    <comparator>To be confirmed</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary objective is to evaluate the clinical benefit (complete response [CR], partial response [PR] and stable disease of at least 24 weeks) of ZD1839 in two groups of patients with metastatic or inoperable locally advanced breast cancer:
 -one group with oestrogen (ER) and progesterone receptor (PgR) negative breast cancer
 -one group with hormone receptor positive (ER and/or PgR) disease progressing after at least two previous hormonal  treatments (tamoxifen and an aromatase inhibitor).
This will be achieved by estimating the clinical benefit rate (CR, PR and SD for 24 weeks) of treatment with ZD 1839 500mg daily in each patient group separately.</outcome>
      <timepoint>To be confirmed</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To estimate the objective tumour response rate (CR and PR).</outcome>
      <timepoint>To be confirmed</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To estimate overall survival.</outcome>
      <timepoint>To be confirmed</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To estimate progression free survival (PFS), based on RECIST criteria.</outcome>
      <timepoint>To be confirmed</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The safety objective of this trial is to further characterize the safety profile of ZD 1839 at a 500mg daily dose.  </outcome>
      <timepoint>To be confirmed</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>A patient is deemed to have clinical benefit if either (1) the RECIST criteria for complete or partial response are at any time satisfied or (2) the RECIST criteria for stable disease are satisfied for at least 24 weeks.  The anticipated accrual over a 12 month study period is 45 hormone receptor positive and a similar number of hormone receptor negative patients.  Analysis of the study will be performed after the last enrolled patient has completed at least 6 months of allocated treatment.   There are no planned interim analyses.</outcome>
      <timepoint>To be confirmed</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Histologically or cytologically confirmed metastatic or inoperable locally advanced breast cancer in one of the following groups:1. Hormone receptor negative (ER and PgR) breast cancer.2. Hormone receptor positive (ER and/or PgR) disease progressing after at least two previous hormonal treatments (tamoxifen and an aromatase inhibitor)Patients must not have had more than one previous chemotherapy regimen for advanced disease; patients must have at least one measurable lesion as defined by RECIST criteria.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Disease progression within 6 months of completion of adjuvant chemotherapy; last dose of systemic anticancer therapy within 21 days before the start of ZD 1839 treatment; newly diagnosed intracerebral metastases; other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>26/06/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>90</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AstraZeneca Australia</primarysponsorname>
    <primarysponsoraddress>To be confirmed</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>ANZ Breast Cancer Trials Group</fundingname>
      <fundingaddress>As the trial is now complete. No further information will be added due to time constraints.</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress>As the trial is now complete. No further information will be added due to time constraints.</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Auckland Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Border Medical Oncology</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Flinders Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Liverpool Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mount Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Melbourne Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincents Hospital, Melbourne</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Queen Elizabeth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Western Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Australian New Zealand Breast cancer Trials Group (ANZ BCTG) Group Coordinator Professor John F Forbes</name>
      <address>Australian New Zealand Breast Cancer Trials Group Ltd
Operations Office
Department of Surgical Oncology
Newcastle Mater Misericordiae Hospital
Locked Bag 7
Hunter Region Mail Centre
Newcastle NSW 2310</address>
      <phone>+61 2 49850113</phone>
      <fax>+61 2 49601539</fax>
      <email>enquiries@anzbctg.newcastle.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Administrative Officer, Data Management</name>
      <address>Australian New Zealand Breast Cancer Trials Group Ltd
Operations Office
Department of Surgical Oncology
Newcastle Mater Misericordiae Hospital
Locked Bag 7
Hunter Region Mail Centre
Newcastle NSW 2310</address>
      <phone>+61 2 49850166</phone>
      <fax>+61 2 49850141</fax>
      <email>enquiries@anzbctg.newcastle.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>